March 29, 2025 06:00 AM EDT

HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The Senate confirmed nominations this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Marks’ exit at FDA rattles an already teetering biotech industry

Lilly's heart disease drug could be dosed as little as once a year, study shows

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

HHS cuts and more from DC; Lyn­dra winds down; 23andMe files for bank­rupt­cy; and more

Editor

Senior Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and more